Selected research
Industry Research
In Vivo Pharmacology Model Industry Research Report 2026
Market perspective
The global In Vivo Pharmacology Model market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the In Vivo Pharmacology Model market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the In Vivo Pharmacology Model market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the In Vivo Pharmacology Model market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of In Vivo Pharmacology Model include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt and Sygnature Discovery, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global In Vivo Pharmacology Model market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to In Vivo Pharmacology Model.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
In Vivo Pharmacology Model Market by Company
NuChem Sciences Inc
Eurofins Discovery
Oncodesign Services
Jubilant Biosys
Pharmaron
Melior Discovery
NUVISAN GmbH
Porsolt
Sygnature Discovery
Aurigene Pharmaceutical Services Ltd
Reaction Biology
Addexbio
Paraza Pharma, Inc
Aragen Life Sciences Ltd
Dalriada
Biocytogen
Charles River Laboratories
Pharmacelsu
HitGen Inc
TCG Lifesciences
In Vivo Pharmacology Model Segment by Type
Inflammation Animal Models
Pain and Neuroscience Animal Models
Diabetes and Metabolic Disorders Animal Models
Oncology Animal Models
Others
In Vivo Pharmacology Model Segment by Application
Cardiovascular Diseases
Neurological Diseases
Autoimmune Diseases
Others
In Vivo Pharmacology Model Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In Vivo Pharmacology Model market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of In Vivo Pharmacology Model and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In Vivo Pharmacology Model.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of In Vivo Pharmacology Model companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inflammation Animal Models
- Pain and Neuroscience Animal Models
- Diabetes and Metabolic Disorders Animal Models
- Oncology Animal Models
- Others
Applications
- Cardiovascular Diseases
- Neurological Diseases
- Autoimmune Diseases
- Others
Companies covered
- NuChem Sciences Inc
- Eurofins Discovery
- Oncodesign Services
- Jubilant Biosys
- Pharmaron
- Melior Discovery
- NUVISAN GmbH
- Porsolt
- Sygnature Discovery
- Aurigene Pharmaceutical Services Ltd
- Reaction Biology
- Addexbio
- Paraza Pharma, Inc
- Aragen Life Sciences Ltd
- Dalriada
- Biocytogen
- Charles River Laboratories
- Pharmacelsu
- HitGen Inc
- TCG Lifesciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 In Vivo Pharmacology Model by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Inflammation Animal Models
- 2.2.3 Pain and Neuroscience Animal Models
- 2.2.4 Diabetes and Metabolic Disorders Animal Models
- 2.2.5 Oncology Animal Models
- 2.2.6 Others
- 2.3 In Vivo Pharmacology Model by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cardiovascular Diseases
- 2.3.3 Neurological Diseases
- 2.3.4 Autoimmune Diseases
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 In Vivo Pharmacology Model Breakdown Data by Type
- 3.1 Global In Vivo Pharmacology Model Historic Market Size by Type (2021-2026)
- 3.2 Global In Vivo Pharmacology Model Forecasted Market Size by Type (2027-2032)
4 In Vivo Pharmacology Model Breakdown Data by Application
- 4.1 Global In Vivo Pharmacology Model Historic Market Size by Application (2021-2026)
- 4.2 Global In Vivo Pharmacology Model Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global In Vivo Pharmacology Model Market Perspective (2021-2032)
- 5.2 Global In Vivo Pharmacology Model Growth Trends by Region
- 5.2.1 Global In Vivo Pharmacology Model Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 In Vivo Pharmacology Model Historic Market Size by Region (2021-2026)
- 5.2.3 In Vivo Pharmacology Model Forecasted Market Size by Region (2027-2032)
- 5.3 In Vivo Pharmacology Model Market Dynamics
- 5.3.1 In Vivo Pharmacology Model Industry Trends
- 5.3.2 In Vivo Pharmacology Model Market Drivers
- 5.3.3 In Vivo Pharmacology Model Market Challenges
- 5.3.4 In Vivo Pharmacology Model Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top In Vivo Pharmacology Model Players by Revenue
- 6.1.1 Global Top In Vivo Pharmacology Model Players by Revenue (2021-2026)
- 6.1.2 Global In Vivo Pharmacology Model Revenue Market Share by Players (2021-2026)
- 6.2 Global In Vivo Pharmacology Model Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of In Vivo Pharmacology Model Head Office and Area Served
- 6.4 Global In Vivo Pharmacology Model Players, Product Type & Application
- 6.5 Global In Vivo Pharmacology Model Manufacturers Established Date
- 6.6 Global In Vivo Pharmacology Model Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America In Vivo Pharmacology Model Market Size (2021-2032)
- 7.2 North America In Vivo Pharmacology Model Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America In Vivo Pharmacology Model Market Size by Country (2021-2026)
- 7.4 North America In Vivo Pharmacology Model Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe In Vivo Pharmacology Model Market Size (2021-2032)
- 8.2 Europe In Vivo Pharmacology Model Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe In Vivo Pharmacology Model Market Size by Country (2021-2026)
- 8.4 Europe In Vivo Pharmacology Model Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific In Vivo Pharmacology Model Market Size (2021-2032)
- 9.2 Asia-Pacific In Vivo Pharmacology Model Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific In Vivo Pharmacology Model Market Size by Country (2021-2026)
- 9.4 Asia-Pacific In Vivo Pharmacology Model Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America In Vivo Pharmacology Model Market Size (2021-2032)
- 10.2 South America In Vivo Pharmacology Model Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America In Vivo Pharmacology Model Market Size by Country (2021-2026)
- 10.4 South America In Vivo Pharmacology Model Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa In Vivo Pharmacology Model Market Size (2021-2032)
- 11.2 Middle East & Africa In Vivo Pharmacology Model Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021-2026)
- 11.4 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 NuChem Sciences Inc
- 12.1.1 NuChem Sciences Inc Company Information
- 12.1.2 NuChem Sciences Inc Business Overview
- 12.1.3 NuChem Sciences Inc Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.1.4 NuChem Sciences Inc In Vivo Pharmacology Model Product Portfolio
- 12.1.5 NuChem Sciences Inc Recent Developments
- 12.2 Eurofins Discovery
- 12.2.1 Eurofins Discovery Company Information
- 12.2.2 Eurofins Discovery Business Overview
- 12.2.3 Eurofins Discovery Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.2.4 Eurofins Discovery In Vivo Pharmacology Model Product Portfolio
- 12.2.5 Eurofins Discovery Recent Developments
- 12.3 Oncodesign Services
- 12.3.1 Oncodesign Services Company Information
- 12.3.2 Oncodesign Services Business Overview
- 12.3.3 Oncodesign Services Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.3.4 Oncodesign Services In Vivo Pharmacology Model Product Portfolio
- 12.3.5 Oncodesign Services Recent Developments
- 12.4 Jubilant Biosys
- 12.4.1 Jubilant Biosys Company Information
- 12.4.2 Jubilant Biosys Business Overview
- 12.4.3 Jubilant Biosys Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.4.4 Jubilant Biosys In Vivo Pharmacology Model Product Portfolio
- 12.4.5 Jubilant Biosys Recent Developments
- 12.5 Pharmaron
- 12.5.1 Pharmaron Company Information
- 12.5.2 Pharmaron Business Overview
- 12.5.3 Pharmaron Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.5.4 Pharmaron In Vivo Pharmacology Model Product Portfolio
- 12.5.5 Pharmaron Recent Developments
- 12.6 Melior Discovery
- 12.6.1 Melior Discovery Company Information
- 12.6.2 Melior Discovery Business Overview
- 12.6.3 Melior Discovery Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.6.4 Melior Discovery In Vivo Pharmacology Model Product Portfolio
- 12.6.5 Melior Discovery Recent Developments
- 12.7 NUVISAN GmbH
- 12.7.1 NUVISAN GmbH Company Information
- 12.7.2 NUVISAN GmbH Business Overview
- 12.7.3 NUVISAN GmbH Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.7.4 NUVISAN GmbH In Vivo Pharmacology Model Product Portfolio
- 12.7.5 NUVISAN GmbH Recent Developments
- 12.8 Porsolt
- 12.8.1 Porsolt Company Information
- 12.8.2 Porsolt Business Overview
- 12.8.3 Porsolt Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.8.4 Porsolt In Vivo Pharmacology Model Product Portfolio
- 12.8.5 Porsolt Recent Developments
- 12.9 Sygnature Discovery
- 12.9.1 Sygnature Discovery Company Information
- 12.9.2 Sygnature Discovery Business Overview
- 12.9.3 Sygnature Discovery Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.9.4 Sygnature Discovery In Vivo Pharmacology Model Product Portfolio
- 12.9.5 Sygnature Discovery Recent Developments
- 12.10 Aurigene Pharmaceutical Services Ltd
- 12.10.1 Aurigene Pharmaceutical Services Ltd Company Information
- 12.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
- 12.10.3 Aurigene Pharmaceutical Services Ltd Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.10.4 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product Portfolio
- 12.10.5 Aurigene Pharmaceutical Services Ltd Recent Developments
- 12.11 Reaction Biology
- 12.11.1 Reaction Biology Company Information
- 12.11.2 Reaction Biology Business Overview
- 12.11.3 Reaction Biology Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.11.4 Reaction Biology In Vivo Pharmacology Model Product Portfolio
- 12.11.5 Reaction Biology Recent Developments
- 12.12 Addexbio
- 12.12.1 Addexbio Company Information
- 12.12.2 Addexbio Business Overview
- 12.12.3 Addexbio Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.12.4 Addexbio In Vivo Pharmacology Model Product Portfolio
- 12.12.5 Addexbio Recent Developments
- 12.13 Paraza Pharma, Inc
- 12.13.1 Paraza Pharma, Inc Company Information
- 12.13.2 Paraza Pharma, Inc Business Overview
- 12.13.3 Paraza Pharma, Inc Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.13.4 Paraza Pharma, Inc In Vivo Pharmacology Model Product Portfolio
- 12.13.5 Paraza Pharma, Inc Recent Developments
- 12.14 Aragen Life Sciences Ltd
- 12.14.1 Aragen Life Sciences Ltd Company Information
- 12.14.2 Aragen Life Sciences Ltd Business Overview
- 12.14.3 Aragen Life Sciences Ltd Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.14.4 Aragen Life Sciences Ltd In Vivo Pharmacology Model Product Portfolio
- 12.14.5 Aragen Life Sciences Ltd Recent Developments
- 12.15 Dalriada
- 12.15.1 Dalriada Company Information
- 12.15.2 Dalriada Business Overview
- 12.15.3 Dalriada Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.15.4 Dalriada In Vivo Pharmacology Model Product Portfolio
- 12.15.5 Dalriada Recent Developments
- 12.16 Biocytogen
- 12.16.1 Biocytogen Company Information
- 12.16.2 Biocytogen Business Overview
- 12.16.3 Biocytogen Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.16.4 Biocytogen In Vivo Pharmacology Model Product Portfolio
- 12.16.5 Biocytogen Recent Developments
- 12.17 Charles River Laboratories
- 12.17.1 Charles River Laboratories Company Information
- 12.17.2 Charles River Laboratories Business Overview
- 12.17.3 Charles River Laboratories Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.17.4 Charles River Laboratories In Vivo Pharmacology Model Product Portfolio
- 12.17.5 Charles River Laboratories Recent Developments
- 12.18 Pharmacelsu
- 12.18.1 Pharmacelsu Company Information
- 12.18.2 Pharmacelsu Business Overview
- 12.18.3 Pharmacelsu Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.18.4 Pharmacelsu In Vivo Pharmacology Model Product Portfolio
- 12.18.5 Pharmacelsu Recent Developments
- 12.19 HitGen Inc
- 12.19.1 HitGen Inc Company Information
- 12.19.2 HitGen Inc Business Overview
- 12.19.3 HitGen Inc Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.19.4 HitGen Inc In Vivo Pharmacology Model Product Portfolio
- 12.19.5 HitGen Inc Recent Developments
- 12.20 TCG Lifesciences
- 12.20.1 TCG Lifesciences Company Information
- 12.20.2 TCG Lifesciences Business Overview
- 12.20.3 TCG Lifesciences Revenue in In Vivo Pharmacology Model Business (2021-2026)
- 12.20.4 TCG Lifesciences In Vivo Pharmacology Model Product Portfolio
- 12.20.5 TCG Lifesciences Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst